دورية أكاديمية
أعرض في EDS

Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML.

التفاصيل البيبلوغرافية
العنوان: Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML.
المؤلفون: Bauer M; Institute of Pathology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle, Germany., Jäkel N; Department of Hematology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle, Germany., Wilfer A; Institute of Pathology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle, Germany.; Krukenberg Cancer Center Halle, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle, Germany., Haak A; Institute of Pathology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle, Germany., Eszlinger M; Institute of Pathology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle, Germany., Kelemen K; Institute of Pathology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle, Germany., Haemmerle M; Institute of Pathology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle, Germany., Al-Ali HK; Department of Hematology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle, Germany.; Krukenberg Cancer Center Halle, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle, Germany., Seliger B; Medical Faculty, Martin Luther University Halle-Wittenberg, Halle, Germany.; Medical Faculty, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, Germany.; Institute of Translational Immunology, Medical School 'Theodor Fontane', Brandenburg an der Havel, Germany., Wickenhauser C; Institute of Pathology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Halle, Germany.
المصدر: Oncoimmunology [Oncoimmunology] 2024 Mar 06; Vol. 13 (1), pp. 2323212. Date of Electronic Publication: 2024 Mar 06 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101570526 Publication Model: eCollection Cited Medium: Internet ISSN: 2162-402X (Electronic) Linking ISSN: 21624011 NLM ISO Abbreviation: Oncoimmunology Subsets: MEDLINE
أسماء مطبوعة: Publication: 2015- : Philadelphia, PA : Taylor & Francis
Original Publication: Austin, TX : Landes Bioscience
مواضيع طبية MeSH: HLA-G Antigens*/metabolism , Bone Marrow*/metabolism, Humans ; Prognosis ; Tumor Microenvironment/genetics ; CD8-Positive T-Lymphocytes
مستخلص: Genetic aberrations and immune escape are fundamental in MDS and CMML initiation and progression to sAML. Therefore, quantitative and spatial immune cell organization, expression of immune checkpoints (ICP), classical human leukocyte antigen class I (HLA-I) and the non-classical HLA-Ib antigens were analyzed in 274 neoplastic and 50 non-neoplastic bone marrow (BM) biopsies using conventional and multiplex immunohistochemistry and correlated to publicly available dataset. Higher numbers of tissue infiltrating lymphocytes (TILs) were found in MDS/CMML (8.8%) compared to sAML (7.5%) and non-neoplastic BM (5.3%). Higher T cell abundance, including the CD8 + T cell subset, inversely correlated with the number of pathogenic mutations and was associated with blast BM counts, ICP expression, spatial T cell distribution and improved patients' survival in MDS and CMML. In MDS/CMML, higher PD-1/PD-L1/PD-L2 and HLA-I, but lower HLA-G expression correlated with a significantly better patients' outcome. Moreover, a closer spatial proximity of T cell subpopulations and their proximity to myeloid blasts showed a stronger prognostic impact when compared to TIL numbers. In sAML - the continuum of MDS and CMML - the number of TILs had no impact on prognosis, but higher CD28 and HLA-I expression correlated with a better outcome of sAML patients. This study underlines the independent prognostic value of the tumor microenvironment in MDS/CMML progression to sAML, which shows the most pronounced immune escape. Moreover, new prognostic markers, like HLA-G expression and spatial T cell distribution, were described for the first time, which might also serve as therapeutic targets.
Competing Interests: No potential conflict of interest was reported by the author(s).
(© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.)
References: PLoS One. 2010 Sep 29;5(9):. (PMID: 20927380)
Blood. 2020 Dec 10;136(24):2812-2823. (PMID: 32730593)
Cancers (Basel). 2021 Oct 16;13(20):. (PMID: 34680337)
Leuk Lymphoma. 2018 Apr;59(4):790-802. (PMID: 28679300)
PLoS One. 2022 Oct 25;17(10):e0275399. (PMID: 36282797)
Annu Rev Pathol. 2016 May 23;11:101-26. (PMID: 27193452)
J Immunother Cancer. 2020 Mar;8(1):. (PMID: 32234847)
Am J Blood Res. 2021 Oct 15;11(5):472-497. (PMID: 34824881)
Curr Oncol Rep. 2019 Mar 23;21(4):37. (PMID: 30904967)
Br J Haematol. 2009 Apr;145(1):64-72. (PMID: 19210506)
BMC Cancer. 2021 Feb 6;21(1):134. (PMID: 33549060)
Lancet Oncol. 2009 Mar;10(3):223-32. (PMID: 19230772)
Ann Oncol. 2015 Feb;26(2):259-71. (PMID: 25214542)
Nature. 2013 Jul 11;499(7457):214-218. (PMID: 23770567)
Cancers (Basel). 2021 Jan 07;13(2):. (PMID: 33430322)
Immunity. 2011 Sep 23;35(3):400-12. (PMID: 21943489)
Front Immunol. 2022 Oct 04;13:1034438. (PMID: 36268012)
Cells. 2022 Jul 20;11(14):. (PMID: 35883692)
Front Cell Dev Biol. 2020 Jul 21;8:672. (PMID: 32793604)
Cancers (Basel). 2021 Feb 04;13(4):. (PMID: 33557271)
Nat Commun. 2020 Apr 20;11(1):1897. (PMID: 32312968)
Science. 2006 Sep 29;313(5795):1960-4. (PMID: 17008531)
Immunity. 2012 Dec 14;37(6):1009-23. (PMID: 23219391)
Blood. 2023 Apr 13;141(15):1817-1830. (PMID: 36706355)
Oncotarget. 2015 Apr 20;6(11):9612-26. (PMID: 25823822)
Nat Cancer. 2023 Jan;4(1):27-42. (PMID: 36581735)
Blood. 2019 Mar 7;133(10):1039-1048. (PMID: 30670444)
Blood Rev. 2023 Jul;60:101072. (PMID: 36934059)
Leukemia. 2014 Jun;28(6):1280-8. (PMID: 24270737)
Exp Hematol Oncol. 2022 Mar 2;11(1):11. (PMID: 35236415)
Leuk Res. 2013 May;37(5):541-6. (PMID: 23453286)
Nucleic Acids Res. 2016 Jul 8;44(W1):W147-53. (PMID: 27190236)
Methods Enzymol. 2020;635:67-79. (PMID: 32122554)
Curr Hematol Malig Rep. 2018 Aug;13(4):244-255. (PMID: 29934935)
Blood. 2016 May 19;127(20):2391-405. (PMID: 27069254)
BMC Immunol. 2019 Jan 11;20(1):4. (PMID: 30634925)
Clin Cancer Res. 2018 Mar 1;24(5):1019-1029. (PMID: 28947565)
Sci Transl Med. 2020 Jun 3;12(546):. (PMID: 32493790)
J Clin Oncol. 2012 Jul 20;30(21):2670-7. (PMID: 22689805)
Cancers (Basel). 2011 Mar 29;3(2):1672-90. (PMID: 24212778)
Cancer. 2021 Oct 15;127(20):3761-3771. (PMID: 34171128)
Blood. 2010 Oct 14;116(15):2742-51. (PMID: 20581309)
J Clin Oncol. 2011 May 20;29(15):1987-96. (PMID: 21483003)
Front Oncol. 2021 Feb 25;11:624742. (PMID: 33718188)
Cancer Discov. 2022 Jan;12(1):31-46. (PMID: 35022204)
Leukemia. 2016 Mar;30(3):666-73. (PMID: 26514544)
J Clin Invest. 2022 Nov 1;132(21):. (PMID: 36099049)
NPJ Precis Oncol. 2022 Jun 3;6(1):33. (PMID: 35661148)
Leukemia. 2018 May;32(5):1094-1105. (PMID: 29487386)
Nat Genet. 2019 Feb;51(2):202-206. (PMID: 30643254)
Sci Rep. 2022 Dec 29;12(1):22557. (PMID: 36581686)
Front Immunol. 2021 Oct 21;12:717527. (PMID: 34745095)
Nat Genet. 2011 Dec 11;44(1):53-7. (PMID: 22158538)
Front Immunol. 2021 Jun 01;12:683401. (PMID: 34140953)
Blood. 2022 Sep 15;140(11):1200-1228. (PMID: 35767897)
Front Immunol. 2021 Mar 09;12:636568. (PMID: 33767702)
فهرسة مساهمة: Keywords: HLA-G; HLA-I; TILs; immune escape; myeloid neoplasm; spatial immune cell organization; tumor microenvironment
المشرفين على المادة: 0 (HLA-G Antigens)
تواريخ الأحداث: Date Created: 20240314 Date Completed: 20240315 Latest Revision: 20240315
رمز التحديث: 20240315
مُعرف محوري في PubMed: PMC10936680
DOI: 10.1080/2162402X.2024.2323212
PMID: 38481730
قاعدة البيانات: MEDLINE
الوصف
تدمد:2162-402X
DOI:10.1080/2162402X.2024.2323212